Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cote

Showing results (141-150 of 213) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced ChondrosarcomaWilliam D Tap, Victor M Villalobos, Gregory M Cote, et al.
Communications Biology|March 9, 2022
Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcomaChristopher E Lietz, Erik T Newman, Andrew D Kelly, et al.
The American Journal of Surgical Pathology|June 11, 2021
Clinical Utility of Anchored Multiplex Solid Fusion Assay for Diagnosis of Bone and Soft Tissue TumorsIvan Chebib, Martin S Taylor, Valentina Nardi, et al.
Scientific Reports|March 12, 2020
MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcomaChristopher E Lietz, Cassandra Garbutt, William T Barry, et al.
Sarcoma|August 21, 2019
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)Brigitte C Widemann, Yao Lu, Denise Reinke, et al.
Future Oncology (London, England)|February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcomaGregory M Cote, Sant P Chawla, George Demetri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2026
A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)Gregory M Cote, Mason Aberoumand, Edwin Choy, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeuticsChristopher E Lietz, Erik T Newman, Andrew D Kelly, et al.
Science Advances|March 31, 2023
Highly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identityRajendran Sanalkumar, Rui Dong, Lukuo Lee, et al.
Nature Communications|March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket studyMrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Pageof 22

Showing results (141-150 of 213) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced ChondrosarcomaWilliam D Tap, Victor M Villalobos, Gregory M Cote, et al.
Communications Biology|March 9, 2022
Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcomaChristopher E Lietz, Erik T Newman, Andrew D Kelly, et al.
The American Journal of Surgical Pathology|June 11, 2021
Clinical Utility of Anchored Multiplex Solid Fusion Assay for Diagnosis of Bone and Soft Tissue TumorsIvan Chebib, Martin S Taylor, Valentina Nardi, et al.
Scientific Reports|March 12, 2020
MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcomaChristopher E Lietz, Cassandra Garbutt, William T Barry, et al.
Sarcoma|August 21, 2019
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)Brigitte C Widemann, Yao Lu, Denise Reinke, et al.
Future Oncology (London, England)|February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcomaGregory M Cote, Sant P Chawla, George Demetri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2026
A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)Gregory M Cote, Mason Aberoumand, Edwin Choy, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeuticsChristopher E Lietz, Erik T Newman, Andrew D Kelly, et al.
Science Advances|March 31, 2023
Highly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identityRajendran Sanalkumar, Rui Dong, Lukuo Lee, et al.
Nature Communications|March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket studyMrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Pageof 22